[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650184":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":40,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":23,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"University of Kansas Medical Center","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"GLP-1RA users",null,"Participants with a history of GLP-1RA use.",{"label":13,"type":10,"description":14,"interventionNames":10},"GLP-1RA nonusers","Participants who have never used a GLP-1RA medication.",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Molly Fain","CONTACT","913-588-5478","mfain3@kumc.edu",[22],{"facility":5,"status":23,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"RECRUITING","Kansas City","Kansas","66160","United States","US",{"type":30,"coordinates":31},"Point",[32,33],-94.62746,39.11417,{"lat":33,"lon":32},[36,37],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},{"name":38,"role":39,"phone":10,"phoneExt":10,"email":10},"Johanna Finkle, MD","PRINCIPAL_INVESTIGATOR",{"type":39,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Johanna Finkle","Clinical Assistant Professor","100650184","gestational-response-outcomes-and-weight-after-glp-1-use-100650184",false,"NCT07743567","Gestational Response, Outcomes, and Weight After GLP-1 Use","GROW","Inclusion Criteria:\n\n* Adult women\n* Less than or equal to 20 weeks gestation at first visit\n* English speaking\n\nExclusion Criteria:\n\n* \\\u003C18 years at time of initial visit\n* Type 2 diabetes\n* History of bariatric surgery\n* Multiple gestation\n* Cannot consent for themselves\n* Cannot read and speak English\n* Incarcerated",true,"FEMALE","18 Years","45 Years",{"count":55,"type":56},400,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn if using GLP-1RA medications for weight loss before pregnancy influences gestational weight gain and pregnancy outcomes. The main aims of the study are to:\n\n* Compare gestational weight gain between women with preconception GLP-1RA exposure and those without exposure.\n* Compare obstetrical outcomes between women with preconception GLP-1RA exposure and those without exposure.\n\nResearchers will compare pregnant women with a history of GLP-1RA use to pregnant women who have not used a GLP-1RA to compare differences.\n\nParticipants will be asked to complete questionnaires at multiple timepoints during and after pregnancy that ask questions about medication history, thoughts and feelings around food, etc.",[60,61,62],"Pregnant Individuals","Obesity & Overweight","Gestational Weight Gain",[64,65,66,67,68,69,70],"Glucagon-like peptide 1 receptor agonist","Pregnancy","Gestational weight gain","Maternal obesity","Pregnancy outcomes","Food noise","Preconception","2026-07-30",{"date":73,"type":74},"2026-08-04","ACTUAL",{"date":76,"type":74},"2026-04-13",{"date":78,"type":56},"2028-04",{"name":5,"class":6},1]